JP2025502891A - 自己免疫性脳炎のサトラリズマブによる治療 - Google Patents

自己免疫性脳炎のサトラリズマブによる治療 Download PDF

Info

Publication number
JP2025502891A
JP2025502891A JP2024543040A JP2024543040A JP2025502891A JP 2025502891 A JP2025502891 A JP 2025502891A JP 2024543040 A JP2024543040 A JP 2024543040A JP 2024543040 A JP2024543040 A JP 2024543040A JP 2025502891 A JP2025502891 A JP 2025502891A
Authority
JP
Japan
Prior art keywords
encephalitis
satralizumab
subject
nmdar
lgi1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502891A5 (cg-RX-API-DMAC7.html
Inventor
孝俊 小澤
広顕 井田
創 伊藤
俊介 吉田
ジリアン スミス
シアン レノン-クライムズ
ガエル クリンゲルシュミット
ビューディンゲン ハンス-クリスチャン フォン
バウマン ハンナ シルバー
ジェームズ オーヴェレル
シャルミラ ラジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2025502891A publication Critical patent/JP2025502891A/ja
Publication of JP2025502891A5 publication Critical patent/JP2025502891A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024543040A 2022-01-19 2023-01-18 自己免疫性脳炎のサトラリズマブによる治療 Pending JP2025502891A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263300893P 2022-01-19 2022-01-19
US63/300,893 2022-01-19
PCT/JP2023/001270 WO2023140269A1 (en) 2022-01-19 2023-01-18 Treatment of autoimmune encephalitis with satralizumab

Publications (2)

Publication Number Publication Date
JP2025502891A true JP2025502891A (ja) 2025-01-28
JP2025502891A5 JP2025502891A5 (cg-RX-API-DMAC7.html) 2026-01-14

Family

ID=87348849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543040A Pending JP2025502891A (ja) 2022-01-19 2023-01-18 自己免疫性脳炎のサトラリズマブによる治療

Country Status (11)

Country Link
US (1) US20250127891A1 (cg-RX-API-DMAC7.html)
EP (1) EP4466018A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025502891A (cg-RX-API-DMAC7.html)
KR (1) KR20240145472A (cg-RX-API-DMAC7.html)
CN (1) CN118900699A (cg-RX-API-DMAC7.html)
AU (1) AU2023209259A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243067A1 (cg-RX-API-DMAC7.html)
IL (1) IL314213A (cg-RX-API-DMAC7.html)
MX (1) MX2024008835A (cg-RX-API-DMAC7.html)
TW (1) TW202337495A (cg-RX-API-DMAC7.html)
WO (1) WO2023140269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010065116A2 (en) 2008-12-02 2010-06-10 The Trustees Of The University Of Pennsylvania The use of il-27-p28 to antagonize il-6 mediated signaling
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
JPWO2020202839A1 (cg-RX-API-DMAC7.html) * 2019-03-29 2020-10-08

Also Published As

Publication number Publication date
AU2023209259A1 (en) 2024-07-18
WO2023140269A1 (en) 2023-07-27
IL314213A (en) 2024-09-01
EP4466018A4 (en) 2026-03-25
MX2024008835A (es) 2024-07-25
KR20240145472A (ko) 2024-10-07
US20250127891A1 (en) 2025-04-24
CA3243067A1 (en) 2023-07-27
TW202337495A (zh) 2023-10-01
EP4466018A1 (en) 2024-11-27
CN118900699A (zh) 2024-11-05

Similar Documents

Publication Publication Date Title
WO2023140269A1 (en) Treatment of autoimmune encephalitis with satralizumab
US20250034265A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
JP2024156984A (ja) 難治性全身型重症筋無力症の処置のための方法
US20230183362A1 (en) Methods for treating prurigo nodularis by administering an il-4r antagonist
EP4058060B1 (en) Type i interferon inhibition in systemic lupus erythematosus
KR20230130681A (ko) Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법
Correa-Díaz et al. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders
Clardy et al. Therapeutic approach to autoimmune neurologic disorders
Yu et al. First‐in‐Human Study of BAT4406F, an ADCC‐Enhanced Fully Humanized Anti‐CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders
KR20090063215A (ko) 캠패스-1h에 의한 다발성 경화증 (ms)의 치료
KR20240053620A (ko) 항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법
JP2022501378A (ja) 視神経脊髄炎の処置のためのエクリズマブ
TW202233676A (zh) 使用抗cd19抗體治療自體免疫性疾病
KR20260033556A (ko) (r)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을투여함으로써 아동, 청소년 및 성인에서 지속성 또는 만성 면역 혈소판감소증을 치료하는 방법
HK40111127A (en) Treatment of autoimmune encephalitis with satralizumab
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
EP4370547A1 (en) Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
HK40107811A (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
WO2020017629A1 (ja) Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис
HK40080317B (en) Type i interferon inhibition in systemic lupus erythematosus
HK40080317A (en) Type i interferon inhibition in systemic lupus erythematosus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251226

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260706